- Home
- TRVI vs TRML Comparison
TRVI vs TRML Comparison
Compare TRVI & TRML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRVI
- TRML
- Stock Information
- Founded
- TRVI 2011
- TRML 2021
- Country
- TRVI United States
- TRML United States
- Employees
- TRVI N/A
- TRML N/A
- Industry
- TRVI Biotechnology: Pharmaceutical Preparations
- TRML Biotechnology: Pharmaceutical Preparations
- Sector
- TRVI Health Care
- TRML Health Care
- Exchange
- TRVI Nasdaq
- TRML Nasdaq
- Market Cap
- TRVI 725.7M
- TRML 598.9M
- IPO Year
- TRVI 2019
- TRML N/A
- Fundamental
- Price
- TRVI $7.01
- TRML $26.74
- Analyst Decision
- TRVI Strong Buy
- TRML Strong Buy
- Analyst Count
- TRVI 10
- TRML 7
- Target Price
- TRVI $19.35
- TRML $50.14
- AVG Volume (30 Days)
- TRVI 2.0M
- TRML 173.4K
- Earning Date
- TRVI 11-05-2025
- TRML 11-06-2025
- Dividend Yield
- TRVI N/A
- TRML N/A
- EPS Growth
- TRVI N/A
- TRML N/A
- EPS
- TRVI N/A
- TRML N/A
- Revenue
- TRVI N/A
- TRML N/A
- Revenue This Year
- TRVI N/A
- TRML N/A
- Revenue Next Year
- TRVI N/A
- TRML N/A
- P/E Ratio
- TRVI N/A
- TRML N/A
- Revenue Growth
- TRVI N/A
- TRML N/A
- 52 Week Low
- TRVI $2.36
- TRML $11.56
- 52 Week High
- TRVI $8.78
- TRML $29.79
- Technical
- Relative Strength Index (RSI)
- TRVI 44.05
- TRML 77.71
- Support Level
- TRVI $7.09
- TRML $22.31
- Resistance Level
- TRVI $8.78
- TRML $24.56
- Average True Range (ATR)
- TRVI 0.43
- TRML 1.26
- MACD
- TRVI -0.07
- TRML 0.22
- Stochastic Oscillator
- TRVI 4.32
- TRML 76.03
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.
About TRML Tourmaline Bio Inc.
Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases.